INTRODUCTION
Antimicrobial peptides (AMPs) are defined as such for their capacity to rapidly inactivate infectious agents [1] [2] [3] [4] [5] . Most AMPs act by disrupting the integrity of the microbial membranes [1] , a feature that is accounted for by two common structural characteristics, that is, a net-positive charge and the propensity to fold into amphipathic structures, which enable these molecules to bind to negatively charged microbial surfaces and then insert into the membranes.
Mammals are equipped with diverse combinations of AMPs. These molecules are synthesized and secreted in large amounts in those tissues that are exposed to environmental microbes, such as skin and mucosal epithelia, to provide an immediate early defense against infection. The protection effected by locally synthesized peptides is reinforced by systemically derived AMPs, most of which are stored in the neutrophil granules and are released on demand at sites of microbial invasion. It is becoming increasingly manifest that many of these peptides act not only as innate microbicidal agents but can mediate a wide range of other biological effects [6 -9] .
The two major AMP families in mammals are the defensins [10] and another group of cationic molecules, classified as cathelicidin peptides [11] [12] [13] . Whereas the defensin structure is based on a common beta sheet core stabilized by three disulfide bonds [10] , cathelicidin AMPs are highly heterogeneous. They range in size from 12 to 80 amino acid residues and cover a wide range of structures [14] . The most widespread AMPs belonging to this family are linear peptides of 23-37 amino acid residues that fold into amphipathic ␣-helices in environments mimicking biological membranes. Other members of this family include a number of small-sized (12-18 residues) molecules with beta-hairpin structures stabilized by one or two disulphide bonds, and a 13-residue linear peptide characterized by a high proportion of tryptophan. Yet other cathelicidin peptides are larger in size (39 -80 amino acid residues) and display repetitive proline motifs forming extended polyproline-type structures. The reason all these molecules have been placed under the same cathelicidin flag, despite showing such a marked structural diversity, is that they are stored in cells in an unprocessed form in which each AMP sequence is joined to a fairly conserved N-terminal prosequence of approximately 100 residues. This is known as the "cathelin" domain ( Fig. 1) and is a hallmark feature of the intracellular storage forms of this group of AMPs. Although the holoprotein, containing the cathelin domain followed by a varied C-terminal antimicrobial domain, is generally termed "cathelicidin," each family member has then been named individually, in some cases by using acronyms (e.g., CRAMP, BMAPs) or one-letter symbols of key amino acid residues present in the antimicrobial sequence, followed by the number of residues (e.g., LL-37, PR-39). In other cases the designation (e.g., indolicidin, protegrin, dodecapeptide) refers to specific features of the antimicrobial domains.
The aim of this review is to provide an overview of the biology of cathelicidins with a focus on those cathelicidin peptides that, in addition to showing microbicidal properties, also exert biological activities unrelated to direct pathogen inactivation and thus have the potential to participate in var-ious other processes connected with host defense and inflammation. In this regard, the most studied cathelicidin peptides are human LL-37, porcine PR-39, and bovine BMAP-28, and their multiple activities and molecular targets will be described here in some detail. LL-37 and BMAP-28 are representative of the ␣-helical type of cathelicidins that are the most widespread and are represented by at least one member in all studied mammals. PR-39 instead has a distinct structure due to an overrepresentation of proline residues, which is shared only by the bovine Bac peptides.
The cathelicidin protein family
Cathelicidins were recognized initially as constitutive components of myeloid-derived cells [13] . A proline-rich peptide named Bac5 played a prominent role both in the discovery of the first family members a decade ago, and in the early elucidation of their biosynthesis and maturation. Bac5 is a Cterminally amidated peptide of 43 amino acid residues, with a polycationic sequence characterized by a repeated proline motif [15] . This peptide was isolated from the bovine neutrophils in the late 80s, together with Bac7, a 60-residue peptide with structural features similar to Bac5, in an effort to characterize the antimicrobial repertoire of bovine leukocytes [16] .
The trigger for the discovery of the cathelicidin family was a PCR amplification step during molecular cloning of Bac5 [17] . In the process of identifying the full-length cDNA, we amplified Bac5 cDNA from bovine myeloid marrow cell mRNA by pairing an oligo-dT primer with a forward oligonucleotide primer derived from a Bac5 cDNA sequence upstream from the peptide coding region. Although this sequence was thought to be unique to Bac5 cDNA, a variety of additional cDNAs were co-amplified by using these primers, and each predicted a different peptide sequence attached to a propiece that showed 75-87% sequence identity to the corresponding propiece of Bac5 [17] . Similarity searches of known proteins in the SwissProt database based on this propiece then revealed a pig leukocyte protein named cathelin [18] , which shared similar size (approximately 11 kDa ) and higher-than-70% sequence identity to the propiece of the bovine peptides. These features strongly supported the argument that cathelin was the processed propiece of a yet-undiscovered pig AMP that belongs to the same family as the cattle peptides. This finding stimulated the search for novel family components with diverse AMP sequences in a variety of other mammals.
Cathelicidin family components have since been found in every mammalian species investigated (Fig. 2) , that is, humans [19 -21] , monkeys [22, 23] , mice [24, 25] , rats [26] , rabbits [27] , guinea pigs [28] , pigs [29 -35] , cattle [17, 36 -40] , sheep [41, 42] , goats [43] , and horses [44] . Each species, however, contains a different set of related genes, which reveal the presence of differential selective pressures. Eleven cathelicidin genes cluster at a CATHL@ locus on bovine chromosome 22q24 [40, 45] , and eight lie in close proximity on sheep chromosome 19 [46] . Based on the number of identified cDNAs and genes [29 -35, 47-49] , the pig cathelicidin family is about the same size as cattle, but most peptide sequences are remarkably different; whereas the cathelin domain is highly conserved (75-80% identity) in the two species [34] . Humans and mice contain one typical cathelicidin each [19, 25] , with the corresponding genes mapped to human chromosome 3 [47] and mouse chromosome 9 [25] , at regions of conserved synteny to which genes for cathelicidins have been mapped in the other species. Rabbits [50] and mice [51] also contain other cathelicidin family members that are more distantly related, but, quite surprisingly, no cathelicidin-related sequences are presently available from non-mammals. Therefore, the evolutionary history of these molecules cannot be traced with certainty. Indeed, the sequences of two pore-forming antimicrobial peptides, putatively belonging to the cathelicidin family and produced in hematopoietic cells within the intestinal submucosa of hagfish, have recently been published [52] . Significantly, an analysis of these sequences indicates that they could assume an ␣-helical structure. The discovery of cathelicidin members in hagfish would imply that ancient cathelicidin ancestors already existed 300 million years ago. However, at the time of writing, the full-length sequences of the hagfish molecules are not available, so that the association of these hagfish peptides with cathelicidin members, as based on the presence of a cathelin-like propiece, has not yet been documented conclusively.
The biosynthesis and maturation process of cathelicidins is illustrated by the results of early biochemical, immunochemical, and functional studies of the granule storage form of Bac5 in bovine myeloid cells. We found that the cathelin-containing propeptides are synthesized in the bone marrow and are stored in a myeloperoxidase-negative subset of the bovine neutrophil granules [53] , named "large granules" [54] . An elastase-specific processing site, as deduced from cDNA [13] , is present in the region that joins the cathelin domain and the AMP sequence in each propeptide. The requirement of elastase for generating active cathelicidin peptides is also supported by the rapid and complete in vitro processing of purified propeptides after addition of minute amounts of this enzyme, and by the inhibition of peptide activation in the presence of an elastasespecific inhibitor [55] . The granule storage forms are not harmful to microbes, as indicated by in vitro antimicrobial assays [55] . Unwanted intracellular processing of these molecules to active AMPs in resting neutrophils is prevented by the segregation of the propeptides and the processing enzyme to separate granule subsets, as also shown by immunoelectron microscopy of bovine neutrophils [56] . Biochemical and Western analyses of the secretion media of activated neutrophils provide evidence that infectious or inflammatory stimuli that result in exocytosis of the secretory and the azurophil granules convey the granule contents extracellularly (or in phagocytic vacuoles in the presence of bacteria), where the C-terminal peptides are freed from the cathelin domain by elastase-dependent proteolytic cleavage of the propeptides [55, 56] .
The elastase-mediated processing of cathelicidins in pig is addressed in elegant in vitro and in vivo studies by Cole et al, which highlight the contribution of cathelicidin peptides to the antimicrobial activity of porcine wound fluid [57] . These studies demonstrate that the maturation of protegrins (cathelicidin members) in a skin wound chamber model can be prevented by locally applying an elastase-specific inhibitor (NEI) [57] . The lack of mature protegrins under these conditions leads to inefficient clearance of bacteria from wound, and the addition of exogenous protegrin or excess elastase in NEI-inhibited wound fluid restores the antimicrobial activity of the fluid [57] . However, in other mammals or in different settings, cathelicidin peptides may be activated by different enzymes. For instance, the myeloid-derived human cationic antimicrobial protein 18 (hCAP-18) stored in the secondary granules of neutrophils [58] is highly susceptible to proteinase 3, a serineproteinase of the azurophils [59] ; whereas the epididymalderived hCAP-18 in seminal plasma is cleaved by the prostatederived protease gastricsin (pepsin C) when exposed to vaginal fluid at low pH [60] .
The cathelin domain
A wealth of published data indicates that cathelicidin AMPs inactivate in vitro a variety of bacteria, fungi, and enveloped viruses with a broad overlap in specificity and significant differences in potency [14, 61, 62] . Evidence is mounting to firmly implicate these peptides in in vivo protection against infection [see below]. Conversely, a limited number of papers are concerned with the function of the cathelin propiece, and the biological role of this evolutionarily conserved domain is still a matter for debate. According to a recent report [63] , the cathelin domain of the human cathelicidin hCAP-18 is endowed with antimicrobial properties after being released by proteolytic processing of the holoprotein. This observation would imply that proteolytic cleavage of hCAP-18 generates two distinct AMPs, LL-37 and cathelin. Based on in vitro assays, the recombinant cathelin (approximately 11 kDa) is active at 16 -32 M against bacterial strains that are resistant to LL-37, so that the two proteins appear to exert complementary antibiotic activities [63] . The mechanism of the antimicrobial activity of cathelin is unlikely to resemble that of cationic AMPs, since this portion of the holoprotein has no net-positive charge and its structure in no way resembles that of known AMPs. Cathelin shows an intriguing sequential and structural similarity to members of the cystatin superfamily of cysteine proteinase inhibitors, at both the protein [18, 64] and gene [40, 65] levels. The structural similarities are highlighted in the recently published X-ray structure of the cathelin motif of porcine protegrin-3, which shows a fold homologous to cystatins [66] . The common evolutionary relatedness of cathelicidin and cystatin family members is supported further by the inhibitory effects exerted by bovine cathelicidins [64, 67] , or of their cathelin domain [63] , on the in vitro activity of cathepsin L, a cysteine proteinase that can contribute to tissue injury. However, the Ki values of cathelicidins generally are in the 10 -7 M range [64, 67] , which are considerably higher than those of cystatins. This may render the physiological significance of this effect questionable and leaves open the possibility of still other significant roles that may have resulted in strong pressure for conservation of this sequence. It is interesting to observe in this regard that the human cathelicidin peptide LL-37 is detected primarily as the uncleaved holoprotein hCAP-18 ( Fig. 3 ) in many settings, for example, wound and blister fluids [68] , phagocytic vacuoles [59] , psoriatic skin [69] , seminal plasma [70] , and associates to plasma lipoproteins in the hCAP-18 form [71, 72] . A possible explanation for the widespread presence of uncleaved hCAP-18 is that the cathelin domain protects the peptide from proteolytic degradation in protease-rich media, although both the mature LL-37 and the holoprotein have been shown to be degraded in vitro and ex vivo in human wound fluid by elastase-producing P. aeruginosa [73] .
The human cathelicidin hCAP-18/LL-37
Among the known cathelicidins, those carrying a C-terminal peptide of the ␣-helical type are present in every mammal thus far investigated and are the lone cathelicidin type identified in some species, for example, humans (hCAP-18/LL-37), rabbits (CAP18), mice (CRAMP), and rats (rCRAMP) (Fig. 2) . Its widespread presence would suggest that the ␣-helical cathelicidin type is the progenitor molecule from which this family differentially expanded in mammals by repeated gene duplications and divergence of the peptide coding sequence, which gives rise to a variety of gene family members in some species (Fig. 2) . Although initially recognized as neutrophil-specific constituents, the ␣-helical-type cathelicidins are distributed widely in cells and tissues. Particularly, hCAP-18/LL-37 ( Fig.  3) , which liberates an ␣-helical peptide (LL-37) of 37 amino acid residues. hCAP-18/LL-37 has been shown by RT-PCR, in situ hybridization and immunohistochemical analysis to be produced in various blood cells populations, that is, NK, ␥␦T cells, B cells, monocytes [74] , and mast cells [75] , in addition to immature neutrophils [58] . The hCAP-18 gene is also expressed in the squamous epithelia of the airways, mouth, tongue, esophagus, intestine, cervix, and vagina [76, 77] ; in sweat [78] and salivary [79] glands; in epididymis and testis [19, 80, 81] . The polypeptide is secreted in human wound [68] , sweat [78] , and airway surface [77] fluids and is especially abundant in seminal plasma [70] , where it may provide a sterile environment during fertilization. Several lines of evidence suggest that LL-37 plays an early defensive role at these sites. For instance, the hCAP-18 gene is up-regulated in skin in response to cutaneous infection or injury [82] and in inflammatory disorders of the skin, such as psoriasis [69, 83] . In contrast, low expression of both hCAP-18 and human beta defensin-2 (HBD-2) genes has been detected in skin lesions from patients with atopic dermatitis. The ensuing deficiency of LL-37 and HBD-2 may provide an explanation for the increased susceptibility of patients with atopic dermatitis to skin infection, compared with patients with psoriasis [69] . A role of LL-37 in prevention of oral bacterial infections is supported by the observation that LL-37 deficiency in neutrophils from patients with morbus Kostmann, a severe congenital neutropenia, correlates with the occurrence of chronic periodontal disease in these patients [84] . Also in favor of the involvement of LL-37 in prevention of bacterial invasion is the finding that hCAP-18 is down-regulated in gut biopsies of patients with Shigella infections, as well as Shigella-infected monocyte and epithelial-derived cell lines [85] . The results of this study suggest that antimicrobial peptide-encoding genes can be repressed by pathogenic microbes as part of a strategy aimed to circumvent immune defenses, resulting in increased virulence. Indirect evidence that endogenous expression of LL-37 protects from skin infections comes from the demonstration that mice null for the CRAMP cathelicidin gene are much more susceptible to skin infection by group A Streptococcus than wild-type mice are [86] . In this respect, it is worth noting that CRAMP and LL-37 are structurally similar and, in addition, both are induced in the skin following skin injury and both are active against group A Streptococcus [82] . The role of LL-37 in host defense against microbes has also been investigated by using a genetic approach based on adenoviral-mediated hCAP-18 gene transfer into respiratory epithelia [87, 88] . When recombinant hCAP-18 is overexpressed in a human bronchial xenograft model, it reverses the cystic fibrosis-specific bacterial killing defect. This finding supports the hypothesis that a deficient activity of AMPs contributes to lung disease in cystic fibrosis [87] . In keeping with these results, transfer of hCAP-18/LL-37 gene into mouse airways results in a decreased bacterial load as well as decreased inflammatory response in P. aeruginosa-infected mice [88] . Furthermore, systemic overexpression of this gene protects D-GalN-sensitized mice injected with LPS or E. coli from septic death [88] , which suggests that LL-37 not only contributes to clearance of bacteria, it also offers systemic protection against the detrimental effects of massive microbial invasion. This action may depend largely on the LPS-binding and LPS-neutralizing properties of LL-37 [89 -92] . Some cathelicidin AMPs bind free LPS with high affinity [93, 94] , and both the human and rabbit peptides have been shown to inhibit LPS-induced cellular responses, such as release of TNF-␣, nitric oxide, and tissue factor [89, 93, 95] , whereas further in vitro studies have assessed the ability of LL-37 to inhibit macrophage activation by other bacterial components (lipoteichoic acid and noncapped lipoarabinomannan) in addition to LPS [92] .
The discovery of additional novel activities unrelated to direct pathogen inactivation may disclose a far more complex role of LL-37 in host defense than earlier suspected. LL-37 has chemotactic effects in vitro, inducing selective migration of human peripheral blood monocytes, neutrophils, and CD4 T cells [74, 96] with a dose-dependent, bell-shaped response, and optimal concentrations that range from 10 -7 to 10 -5 M. The chemotactic activity is not affected by serum [96] , at serum concentrations that are known to inhibit the in vitro antimicrobial effects of LL-37 [97] . This suggests that the two activities are mediated by different mechanisms. This hypothesis is further supported by the finding that the chemotactic activity of LL-37 depends on binding to formyl peptide receptor-like 1 (FPRL1, see ref. [98] for an overview of the FPR family), as indicated by the identification of an agonistic ligand specific for this receptor in monocytes, and by the ability of LL-37 to chemoattract cells that express FPRL1 gene, or cells transfected for FPRL1 gene expression [96] . LL-37 would thus contribute to immune responses by recruiting inflammatory and immune cells that express functional FPRL1. LL-37 is also chemotactic for rat peritoneal mast cells (MCs), seemingly through different receptor(s), as suggested by a competitive binding assay by using a FPRL1-specific agonist [99] , with an optimal concentration of 5 g/ml. In addition, LL-37 induces histamine release and intracellular Ca 2ϩ mobilization in these cells [100] . MCs are among the first inflammatory cells to encounter invading pathogens, which are preferentially located at host/environment interface. These cells can initiate sitespecific inflammation by phagocytosing and killing opsonized bacteria and through neutrophil recruitment [101] . It is interesting to note in this respect that MCs are not only a target but are also a source of LL-37, as shown by immunohistochemical analysis of dermis [75] , although the peptide may not be secreted extracellularly [75] . As a cellular component of MCs, LL-37 may contribute to the intraphagolysosome microbial killing [75] . In addition, because it is synthesized and released at inflammatory sites by both resident and inflammatory cells, this peptide may form chemotactic gradients and help with MC recruitment. Furthermore, LL-37-induced MC degranulation would lead to release of inflammatory mediators, including neutrophil chemoattractants and histamine [100] , which would increase vascular permeabilization thus favoring neutrophil infiltration of inflamed tissues. In this scenario, LL-37 may play a role in infected epithelia as a direct antimicrobial effector and as a mediator of positive amplification loops of innate and immune responses, by participating in the recruitment of more and additional types of leukocytes.
This picture may be enriched further by the suggested ability of LL-37 to alter transcriptional responses, as assessed by gene array-based studies [92] . According to these studies, LL-37 at 50 -100 g/ml regulates a number of genes in the murine macrophage cell line RAW 264.7 and in the human epithelial cell line A549, some of which are anti-inflammatory and some have pro-inflammatory roles. Among the genes that are predicted to be up-regulated are chemokine and chemokine receptor genes [92] , which suggests that direct migration of immune cells, and possibly other cellular responses, may be induced by this peptide through modulation of gene expression in target cells. More in-depth studies, however, are required to identify the interacting molecule in these cells, to elucidate the regulation pathway involved, and to explain the biological significance of this activity. The in vitro concentrations required are high, compared with those observed for other in vitro activities of LL-37. However, the fact that high concentrations of hCAP-18 have been detected in seminal plasma (range of 41.8 to 142.8 g/ml from 10 healthy donors [80] ) compared with the plasma lipoprotein-associated polypeptide (approximately 1.2 g/ml plasma) [102] , suggests that it could be present in sufficiently large amounts in some in vivo settings.
In addition to its capability to augment host defenses, LL-37 appears to play a role in repair of damaged tissue and wound closure, by promoting wound neovascularization [103] and re-epithelialization of healing skin [104] . High levels of LL-37 expression are detected in human skin upon wounding, both in vivo [82, 104] and in a non-inflammatory ex vivo wound healing model composed of organ-cultured human skin [104] . Evidence for the involvement of this peptide in re-epithelialization of healing skin epithelium is provided by the ability of LL-37-specific antibodies to inhibit this process in the ex vivo wound healing model [104] . The precise mechanism of this activity has not been clarified, but lack of immunoreactivity for the proliferation marker Ki67 in the LL-37 antibody-inhibited wound argues for a role of the peptide in the proliferative step [104] . In this context, LL-37 may also induce cutaneous wound vascularization, based on the finding that application of exogenous LL-37 results in angiogenesis both in the chorioallantoic membrane assay and in a rabbit hind-limb model of ischemia [103] . The ability of this peptide to stimulate proliferation of cultured HUVECs and to cause endothelial sprouting from hamster aortic rings strongly suggests that the angiogenic effect depends on direct activation of endothelial cells [103] , a process that appears to be mediated by interaction of LL-37 with FPRL1 expressed on endothelial cells [103] .
BMAP and Bac peptides in cattle
In contrast with a single member of this family being present in humans, a variety of cathelicidin peptides are found in cattle. Their marked structural diversity suggests distinct functional capabilities of these molecules and a possibly diversified biological role in host defense. In this regard, it is worth comparing the in vitro antimicrobial activity of ␣-helical (BMAP-27 and BMAP-28, acronym for "Bovine Myeloid Antimicrobial Peptides"; [39] ), and proline-rich (Bac5 and Bac7) bovine peptides [15, 16] . We have shown that BMAPs rapidly permeabilize and kill in vitro a wide range of bacteria and fungi in the low micromolar and submicromolar range of peptide concentrations [39] , whereas under the same experimental conditions, the proline-rich type peptides almost exclusively target gramnegative bacteria [16] . BMAPs are hemolytic in vitro at concentrations that are approximately tenfold higher than those microbicidal, and assays based on cellular uptake of propidium iodide and release of the cytoplasmic enzyme LDH indicate that they are toxic to cultured blood cells and to blood cell- [105] , epithelial-, and fibroblast-derived (unpublished data) cell lines, with a higher susceptibility of hematopoietic tumor cell lines versus normal leukocytes, and of in vitro activated versus resting human lymphocytes [105] . Conversely, under the same experimental conditions, the proline-rich Bac peptides are not lytic to mammalian cells (unpublished data).
The cytotoxicity induced by BMAP-28 (sequence in Fig. 3 ) has been investigated by flow cytometry and confocal microscopy of activated human lymphocytes and hematopoietic and fibroblast-derived ( [105, 106] and unpublished data) cell lines. This molecule causes cell membrane permeabilization, as indicated by propidium iodide uptake, with early Ca 2ϩ influx [105] , and this event is followed by apoptosis in a variable proportion of the cells, as determined by analysis of DNA laddering [105] , by scoring picnotic nuclei, and by in situ terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (unpublished data). The apoptotic effects likely depend on peptide-mediated induction of the mitochondrial permeability transition pore (MPTP), as suggested by the ability of BMAP-28 to target mitochondrial membranes in both single cells and isolated mitocondria, and to induce cyclospo-rine-inhibitable decrease of the inner mitochondrial membrane potential and release of cytochrome c [106] .
Whereas the higher toxicity of BMAP-28 towards transformed versus normal cells underscores the potential contribution of neutrophils in causing active death of tumor cells, the susceptibility of proliferating versus resting lymphocytes may implicate this peptide in the resolution of inflammation. The concentration of BMAP-28 secreted at inflammation sites likely correlates with the number of accumulating neutrophils. Early in the course of inflammation, BMAP-28 would be present in the low amounts required for pathogen inactivation, whereas, with amplified neutrophil recruitment, the local peptide concentration may gradually increase to the extent required to cause death of activated (and/or possibly, infected) host cells. Our in vitro studies indicate that a substantial amount of BMAP-28-susceptible cells die by apoptosis, which suggests that this peptide could contribute via this mechanism to prevent excessive tissue injury caused by release of enzymes and other toxic cellular components.
The toxicity of BMAPs is reflected by the fact that their abundance is relatively low in neutrophils, as revealed by Northern and Western analyses of immature and mature neutrophils (unpublished observations), as compared with Bac5 and Bac7, which altogether comprise 4% of total neutrophil proteins, as based on immunochemical quantification of the storage forms [56] . Conversely, RT-PCR analysis of bovine tissues points to a wider tissue distribution of BMAP peptides (unpublished data) compared with the myeloid-restricted tissue distribution of Bac5 [107] . That distinct members of this gene family may be differentially expressed and regulated in cattle is also supported by expression studies of Bac5 (Fig. 3) in neutrophils. Like the other bovine cathelicidins, Bac5 is actively synthesized in bone marrow immature neutrophils, and its biosynthesis is turned off in fully differentiated neutrophils [107] . Yet, we have detected high levels of expression of this gene in inflammatory neutrophils infiltrates by in situ hybridization of lung samples from animals with airways infections, which suggests that the expression of this gene can be reinduced in mature neutrophils [107] . Accordingly, stimulation of cultured peripheral neutrophils with bacterial lysates or bacterial lipopolysaccharide results in up-regulation of Bac5 gene expression, as revealed by RT-PCR and Northern blotting, and in extracellular release of the newly synthesized polypeptide [107] . No BMAP-related transcripts are detected by RT-PCR in neutrophils under these conditions. Notably, Bac5 mRNA is present at detectable levels in these cells only 12-20 h after cell activation. This delayed induction time could be consistent with the need to maintain a prolonged antimicrobial defense at sites of infection, but it could also suggest a role of the newly synthesized Bac5 in activities unrelated to direct bacterial killing. The overall structural similarity of Bac5 to PR-39 (Fig. 3) , a multifunctional, prolinerich, porcine cathelicidin peptide of 39 amino acid residues [29, 108] , might support the latter hypothesis.
PR-39, a porcine cathelicidin peptide PR-39 was initially characterized as an antibacterial factor [108] and was later suggested to potentially affect a number of biological responses by acting as a molecular signal. The first evidence for a signaling role of PR-39 was the isolation of a factor capable of inducing syndecan-1 and -4 in cultured mesenchimal cells from wound fluid [109] . The syndecaninducing factor turned out to be identical to PR-39, which likely is released in wound fluid by recruited neutrophils. Syndecans are cell-surface heparan sulfate proteoglycans that are involved in biological processes, such as regulation of blood coagulation, cell adhesion, and wound repair [110] . Syndecan-1 expression in mesenchymal cells is increased during wound repair, which causes the cells to become more responsive to numerous effector molecules, including heparinbinding growth factors such as fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and transforming growth factor ␤ (TGF-␤) [110] . Syndecan members are thought to contribute to wound repair by regulating cell proliferation and migration in response to these effectors. The syndecaninducing activity of PR-39 suggests that the peptide may function as a signaling molecule in wound repair.
The mechanism by which PR-39 can alter mammalian gene expression has been investigated by using PR-39(15), a 15-residue, biologically functional fragment [111] . This molecule rapidly enters cells without causing membrane damage and selectively binds cytosolic proteins containing Src homology 3 (SH3) domains, as predicted by the presence of SH3-binding motifs in its sequence, including a RxxPxxP motif at the N-terminus [111] . In vitro experiments indicate that PR-39 (15) binds various recombinant and native SH3-containing proteins, including p130
Cas [111] , an adapter protein that has been implicated in numerous signaling pathways [112] , and induces a redistribution of this protein from cytosol to cytoskeleton in endothelial cells, leading to activation of p130 Cas -associated signaling pathways. Further SH3-containing target molecules of PR-39, including the regulatory subunit of PI3-kinase, PI3-kinase p85␣, have been identified by transfecting the PR-39 gene in NIH/3T3 fibroblasts transformed with human activated k-ras [113] .
Other in vitro studies suggest that PR-39 is chemotactic for neutrophils at 0.5-2 M [114] , although the cellular receptor for this activity has not been identified and inhibits the phagocyte NADPH oxidase activity at slightly higher concentrations [115] , which points to the involvement of this peptide in the regulation of acute inflammation. The NADPH oxidase catalyzes the reduction of molecular oxygen to superoxide anion, leading to production of reactive oxygen species. These are essential components of early host defense, although their toxicity can cause significant tissue injury during inflammation [116] . PR-39 inhibits NADPH oxidase by blocking assembly via interaction with SH3 domains, which are present in the cytosolic subunit p47 phox and are responsible for its interaction with the membrane component p22 phox [115] . PR-39 is also an inducer of angiogenesis in cell culture and in vivo in mouse myocardium [117] . This effect appears to be mediated by the inhibition of ubiquitin-proteasome-dependent degradation of the hypoxia-inducible factor HIF-1␣ [117] , which up-regulates the expression of angiogenesis-related genes, including vascular endothelial growth factor (VEGF) [118] , and is therefore distinct from the one described for LL-37 [103] . Actually, this activity of PR-39 would provide a link between the two major stimulants of angiogenesis, inflam-mation, and hypoxia, in that a peptide released during the inflammatory response promotes an increased concentration of HIF-1␣, which mediates the hypoxia effects.
Furthermore, PR-39 can bind the ␣7 subunit of the 26S proteasome, as determined in a yeast two-hybrid screening of a mouse cDNA library, and can block the ubiquitin-proteasome pathway-mediated degradation of the NF-B inhibitor IB␣ without affecting overall proteasome activity [119] . The inhibition of proteasome-dependent degradation of IkB␣ results in IB accumulation in cells stably expressing PR-39, and this in turn abolishes induction of NF-B-dependent gene expression both in vitro and in in vivo mouse models of acute pancreatitis and myocardial infarction [119] . A functional consequence of PR-39-mediated inhibition of NF-B activity is a decrease in the expression of the endothelial adhesion proteins VCAM-1 and ICAM-1, both in cell culture and in the setting of acute myocardial infarction in transgenic mice expressing PR-39 in cardiac myocytes. This might explain, at least in part, the reduced adherence of polymorphonuclear cells to coronary vascular endothelium and the reduced injury observed in mouse and rat models of myocardial ischemia-reperfusion after treatment with PR-39 [120] . It is unclear whether inhibition of IkB degradation is also responsible for the inhibition of HIF-1␣ degradation.
Collectively, these studies suggest that PR-39 may have a wide range of effects in different cell types. The ability of PR-39 to bind SH3 domain-containing proteins may reconcile all these findings and provide an explanation for the capacity of PR-39 to mediate such a variety of effects. However, the relevance of these activities in (patho)physiological settings remains to be established and, in this respect, an intriguing observation that may limit the general biological significance of these effects is the apparent absence of PR-39 homologues in humans.
Conclusions
For several years after the discovery of mammalian AMPs, speculation about the biological role of these peptides was mostly limited to their direct antimicrobial activity, based on their ability to interact with microbial components. The subsequent finding that various defensins and some cathelicidin peptides can also interact with host cells and trigger a variety of activities unrelated to direct microbial killing [6 -9] has changed the way we look at these molecules. Our perception has changed from that of considering them isolated soldiers in a first-line trench of innate immunity to effector molecules highly integrated with other mediators of host defense, helping to orchestrate a variety of inflammatory and immune responses, and participating in the cross-talk between innate and adaptive immunity.
It is remarkable, considering their small size (the cathelicidin peptides LL-37 and PR-39, for instance, are, respectively, 37 and 39 amino acid residues) and their relatively simple structures, that these peptides could contain all the necessary information to exerting multiple and diverse actions, which in most cases require specific molecular interaction. It is also remarkable that a number of overlapping activities are displayed by peptides that are structurally quite diverse. In this respect, LL-37 (␣-helical) and PR-39 (extended proline-rich) combine features of AMPs, chemoattractants, and growth factors with defensin members (␤-sheets) [8, 9] . This underlines what appears to be a characteristic feature of innate immunity: an apparent redundancy in the activities of innate effector molecules that has entailed a substantial degree of functional convergence on processes that are crucial to an efficient protection of the host against infection, that is, rapid clearance of bacteria, mobilization of immune responses, and repair of damaged barrier epithelia.
Future research should aim to better clarify the molecular mechanisms underlying all these activities but, also important, to assess how these activities impact on in vivo settings. In this respect, the experimental conditions used may not adequately reflect the complexity of the inflammatory sites where AMPs are secreted and the fact that the recruitment of different cell types makes this microenvironment crowded with molecules, some of which may interfere with the AMP activities in terms of synergy, competition, or inhibition.
Additional studies should aim to identify novel activities also by other cathelicidin peptides. We are encouraged by the fact that each new piece in the puzzle seems to fall into place in a fascinating picture, although it is a far more ample, complex, and relevant picture than we ever suspected a few years ago.
